Want to see KR:199800 full AI Analyst Report?
Top Page
ToolGen Incorporated
(199800)
Select Model
Select Model
Rating:43Neutral
Price Target:
₩27,068.00
Action:N/A
Date:10/28/26
The score is held down primarily by weak financial quality—large operating losses, negative ROE, and sustained negative operating/free cash flow—despite strong revenue growth, very high gross margins, and low balance-sheet leverage. Technicals add further pressure as the stock trades below major moving averages with negative MACD, while valuation is not supportive due to negative earnings and no dividend yield data.
Positive Factors
Revenue growth and gross margin
Strong revenue growth alongside an approximately 92% gross margin indicates that ToolGen’s gene-editing offerings can generate substantial gross profit from expanding sales. If maintained, this combination provides a platform for reinvestment and eventual operating leverage as the company develops its business.
Negative Factors
Persistent operating losses
Deeply negative operating and net margins show that revenue growth is not yet translating into a profitable operating model. The reversal from 2024 profit to large 2025 and TTM losses weakens earnings quality and may require continued external funding while development activities continue.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and gross margin
Strong revenue growth alongside an approximately 92% gross margin indicates that ToolGen’s gene-editing offerings can generate substantial gross profit from expanding sales. If maintained, this combination provides a platform for reinvestment and eventual operating leverage as the company develops its business.
Read all positive factors
ToolGen Incorporated (199800) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩291.21B
Dividend YieldN/A
Average Volume (3M)26.15K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth116.74%
EPS Growth-482.50%
CountryKR
Employees80
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-4355.53
Shares Outstanding9,774,629
10 Day Avg. Volume21,169
30 Day Avg. Volume26,147
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)11.87
Price to Sales (P/S)507.38
P/FCF Ratio-32.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ToolGen Incorporated Business Overview & Revenue Model
Company Description
ToolGen Inc. is a biotechnology firm dedicated to the research and development of cutting-edge genome editing technologies. The company supplies a variety of ready-to-use reagents for gene engineering experiments, including purified gRNA/Cas9, sta...
ToolGen Incorporated Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
66
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.91B | 1.31B | 890.96M | 1.10B | 743.46M | 1.60B |
| Gross Profit | 1.76B | 1.14B | 673.03M | 934.96M | 558.40M | 1.09B |
| EBITDA | -36.87B | -33.90B | 10.65B | -40.37B | -17.07B | -19.79B |
| Net Income | -39.12B | -36.76B | 6.23B | -42.34B | -18.18B | -20.73B |
Balance Sheet | ||||||
| Total Assets | 51.31B | 61.65B | 75.48B | 93.45B | 75.43B | 87.67B |
| Cash, Cash Equivalents and Short-Term Investments | 19.06B | 30.18B | 48.96B | 64.65B | 52.70B | 72.25B |
| Total Debt | 168.41M | 1.75B | 14.01B | 60.43B | 19.98M | 92.96M |
| Total Liabilities | 4.81B | 5.80B | 17.04B | 63.36B | 4.96B | 3.01B |
| Stockholders Equity | 46.50B | 55.85B | 58.44B | 30.09B | 70.47B | 84.66B |
Cash Flow | ||||||
| Free Cash Flow | -23.87B | -20.67B | -16.99B | -21.59B | -20.37B | -15.45B |
| Operating Cash Flow | -21.76B | -20.22B | -16.46B | -14.91B | -14.99B | -14.83B |
| Investing Cash Flow | 13.35B | 12.47B | -2.59B | -716.21M | 17.61B | -57.98B |
| Financing Cash Flow | 401.23M | 988.59M | 810.89M | 33.96B | 887.51M | 70.60B |
ToolGen Incorporated Technical Analysis
Neutral
―
Price Trends
33436.00
Negative
37090.96
Negative
51085.03
Negative
Market Momentum
-1608.70
Positive
43.85
Neutral
31.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:199800, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 31270.00, equal to the 50-day MA of 33436.00, and equal to the 200-day MA of 51085.03, indicating a bearish trend. The MACD of -1608.70 indicates Positive momentum. The RSI at 43.85 is Neutral, neither overbought nor oversold. The STOCH value of 31.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KR:199800.
ToolGen Incorporated Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩613.71B | 13.10 | ― | 0.49% | 51.28% | 124.70% | |
57 Neutral | ₩38.16B | 16.52 | ― | ― | -3.47% | 98.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₩254.79B | -63.16 | ― | ― | -17.13% | 1.63% | |
43 Neutral | ₩291.21B | -16.97 | ― | ― | 116.74% | -482.50% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:199800
ToolGen Incorporated
29,800.00
-26,756.31
-47.31%
KR:002630
ORIENTBIO, Inc.
1,288.00
-972.00
-43.01%
KR:005690
Pharmicell Co., Ltd
10,230.00
-8,267.08
-44.69%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-8,030.00
-75.05%
KR:064550
Bioneer Corporation
7,070.00
-7,430.00
-51.24%
KR:228760
Genomictree, Inc.
10,400.00
-9,750.00
-48.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.